Table 1.
Clinical and biologic characteristics of the severe acute respiratory syndrome coronavirus 2–infected group
| Characteristic | Result |
| Clinical | |
| Age (yr) mean (min; max) (n=16) | 68.2 (49; 95) |
| Women % (n=16) | 31.3 |
| Body mass index (kg/m2) mean (min; max) (n=16) | 30.7 (20.7; 39.6) |
| Medical history | |
| Hypertension % (n=16) | 62.5 |
| Diabetes % (n=16) | 56.3 |
| CKD % (n=14) | 42.9 |
| Active cancer or history % (n=14) | 12.5 |
| Cardiovascular disease % (n=16) | 43.8 |
| Immunocompromise status % (n=16) | 25 |
| Asthma/COPD % (n=16) | 0 |
| Nonsmoker % (n=14) | 78.6 |
| RAAS inhibitors drugs % (n=16) | 50 |
| Hydroxychloroquine used during hospitalization % (n=16) | 87.5 |
| Contrast products injection during hospitalization % (n=16) | 18.8 |
| Antiplatelets used before hospitalization % (n=16) | 43.8 |
| Anticoagulation during hospitalization % (n=16) | 75 |
| Hospital stay length (d) median (IQR) (n=16) | 14 (7.5–22.5) |
| Severity | |
| ICU admission % (n=16) | 62.5 |
| Thorax CT scanner staging % (n=16) | |
| Minor (<10%) | 18.8 |
| Mild (10%–50%) | 37.5 |
| Severe (>50%) | 43.7 |
| Renal severity | |
| AKI % (n=16) | 62.5 |
| CVVH initiation during hospitalization % (n=16) | 18.5 |
| 30% decrease of eGFR during hospitalization % (n=16) | 50 |
| Proteinuria at D0 >500 mg/g of urine creatinine % (n=15) | 53.3 |
| Hematuria at D0 % (n=13) | 53.8 |
| Biologic | |
| ABO group % (n=14) | |
| A–B–AB–O | 64.3–14.3–0 –21.4 |
| Lymphocytes at D0 (/mm3) median (IQR) (n=16) | 720 (520–1440) |
| Lymphocytes at end of hospitalization (/mm3) median (IQR) (n=15) | 970 (530–1280)a |
| Platelet at D0 (×1000/mm3) mean (min; max) (n=16) | 211.4 (79; 417) |
| Platelet at end of hospitalization (×1000/mm3) mean (min; max) (n=15) | 230.3 (26; 457)a |
| C-reactive protein at D0 (mg/L) mean (min; max) (n=16) | 166.5 (4.4; 382.4) |
| C-reactive protein at end of hospitalization (mg/L) mean (min; max) (n=15) | 195.5 (3.8; 311.9)a |
| Fibrinogen (g/L) at D0 median (IQR) (n=16) | 7.18 (4.83–7.72) |
| Fibrinogen (g/L) at end of hospitalization, median (IQR) (n=15) | 6.96 (5.01; 7.86)a |
| Procalcitonin at D0 (µg/L) median (IQR) (n=13) | 0.33 (0.16–0.83) |
| D-dimer at D0 (µg/L) mean (min; max) (n=11) | 1309.5 (329; 2991) |
| LDH at D0 (U/L) mean (min; max) (n=16) | 532.8 (195; 881) |
| CPK at D0 (U/L) median (IQR) (n=16) | 286.5 (181.5–445) |
| eGFR (before hospitalization) (n=13) | |
| 60–90 ml/min per 1,73 m2 % | 46.2 |
| <60ml/min per 1,73 m2 % | 23.1 |
| <30 ml/min per 1,73 m2 % | 0 |
| Serum creatinine at D0 (mg/dl) median (IQR) (n=16) | 1.07 (0.83–1.27) |
| Serum creatinine at end of hospitalization (mg/dl) median (IQR) (n=16) | 0.96 (0.68–1.62)a |
| Potassium at D0 (mmol/L) mean (min; max) (n=16) | 4.16 (3.55; 4.63) |
| Proteinuria at D0 (mg/g of urine creatinine), median (IQR) (n=15) proteinuria at D7 (mg/g of urine creatinine) median (IQR) (n=10) | 580 (320–830) |
| 650 (400–1520)b | |
| Delay biopsy (n=16) | |
| <60 (min) % | 62.5 |
| 60–120 (min) % | 12.5 |
| 120–180 (min) % | 25 |
COPD, chronic obstructive pulmonary disease; D0, day 0 of hospital admission; D7, day 7 after hospital admission; RAAS, renin angiotensin aldosterone system; IQR, interquartile range; ICU, intensive care unit; CT, computed tomography; CVVH, continuous venovenous hemofiltration; LDH, lactate dehydrogenase; CPK, creatinine phospho-kinase.
a
No statistical difference observed between D0 and the end of hospitalization.
b
No statistical difference observed between D0 and D7.